Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Clinical Trial Results The STEP clinical trials established semaglutide as the most effective brand-name weight loss medication
Survodutide (also known as BI 456906) is an investigational peptide developed through a partnership between Boehringer Ingelheim and Zealand Pharma
Tirzepatide (Mounjaro, Zepbound) Tirzepatide targets both GLP-1 and GIP receptors, producing greater average weight loss than semaglutide in head-to-head trials, typically 20 to 25 percent of body weight
FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction that keeps these damaged zombie cells alive, without harming healthy cells
US$ 20.10
US$ 23.69
US$ 27.99
US$ 27.63
US$ 23.73
